Recently,  China Close-Up, a feature column by Xinhuanet, highlighted a standout case of Chinese HPV vaccine technology going globally, showcasing the collaboration among Xiamen Innovax Biotech Co., Ltd. (IX )， Thailand’s National Vaccine Institute (NVI), Chulalongkorn University and Global Biotech Products Co., Ltd.  (GBP) in the field of HPV vaccines.

From supplying the HPV bivalent vaccine Cecolin to support Thailand’s National Immunization Program, to advancing technology transfer and local manufacturing cooperation for the HPV 9-valent vaccine, IX is steadily expanding its role in Thailand’s cervical cancer prevention efforts. Through reliable vaccine supply, strong technical expertise, and long-term localization efforts, IX is contributing to cervical cancer prevention and public health capacity building in Thailand.

Thailand remains one of the countries with a significant cervical cancer burden. According to Xinhuanet, approximately one new cervical cancer case is diagnosed every hour in Thailand, and one woman dies from the disease every two hours. HPV vaccination, as a primary prevention measure against cervical cancer, plays a critical role in improving protection among eligible populations and advancing cervical cancer prevention efforts.

However, during the early phase of Thailand’s HPV vaccination rollout under the National Immunization Program, the country faced challenges caused by the global shortage of HPV vaccine supply. In an interview, Dr. Nakorn Premsri, Director of Thailand’s National Vaccine Institute, stated that the strong partnership between NVI and IX, particularly through the supply of the HPV bivalent vaccine for the national program, effectively helped Thailand address the global supply shortage.

Since 2023, IX has supplied its HPV bivalent vaccine Cecolin to Thailand’s National Immunization Program, supporting the government’s “1 Million Doses in 100 Days” vaccination campaign. To date, more than 2 million doses of the HPV bivalent vaccine developed by IX have been administered in Thailand, with over 90% of school-age children completing vaccination. Professor Thanyavee Puthanakit from the Faculty of Medicine at Chulalongkorn University noted in the report that this achievement will lay the foundation for future cancer prevention in this generation.

The robust supply of the HPV bivalent vaccine has provided important support for expanding vaccination coverage among eligible populations in Thailand, while cooperation on the HPV 9-valent vaccine points toward long-term and sustainable local capacity building.

In July 2024, with policy support from Thailand’s National Vaccine Institute (NVI), IX and GBP officially signed a technology transfer agreement for the HPV 9-valent vaccine to advance systematic cooperation in localized production. In the report, Mr. Prasert, Managing Director of GBP, stated that technology transfer involves not only manufacturing processes, but also quality control, laboratory capability, and the establishment of a comprehensive quality management system.

With coordination and support from NVI, IX and GBP are jointly advancing technology transfer activities related to the HPV 9-valent vaccine, aiming to strengthen Thailand’s local vaccine manufacturing and supply capabilities while improving access to high-quality, affordable, and sustainable HPV vaccines for local populations.

Dr. Nakorn Premsri also noted in the report that the global supply system for HPV 9-valent vaccines remains fragile. Thailand’s goal is not only to secure domestic supply, but also to expand access across ASEAN and potentially to other countries and regions in the future. He expressed hope that “In our collaboration, we can provide affordable vaccines to Thailand, the region, and all developing countries.”

Meanwhile, the team at Chulalongkorn University continues to collaborate with IX on clinical research, including the development of testing methods for evaluating immune responses to HPV vaccines, providing important scientific references for immunogenicity assessment and public health applications.

In the Xinhuanet report, Mr. Prasert, Managing Director of GBP, also shared his expectations for the project from the perspective of a father. He said that if every father knew that a vaccine could help prevent cancer, they would want their daughters to be vaccinated. He hopes this collaboration will bring health and well-being to more families, fathers, and daughters.

From China to Thailand, and from product supply to technology collaboration, Chinese HPV vaccine technology is providing a new practical model for global cervical cancer prevention through accessible, affordable, and sustainable solutions. As Xinhua News stated in its report: “The true value of a technology lies in where it reaches and whom it benefits.”

Looking ahead, IX will continue to uphold an open and collaborative approach, working with global partners to improve HPV vaccine accessibility through high-quality vaccine products, strong technical capabilities, and long-term international cooperation, contributing to the acceleration of global cervical cancer elimination and a more equitable and resilient public health future.